European approach to adjuvant treatment of intermediate- and high-risk malignant melanoma

Seminars in Oncology

Volumn 29, Issue 4, 2002, Pages 382-388

  Eggermont, Alexander M M ^a,b   Gore, Martin ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; CARMUSTINE; CISPLATIN; DACARBAZINE; GANGLIOSIDE GM2; INTERLEUKIN 2; MELACINE; TAMOXIFEN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EUROPE; HUMAN; MELANOMA; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; VACCINATION;

EID: 0036337954     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.34117     Document Type: Article

References (52)

1. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm
2. Wide versus narrow surgical excision in thin (<2 mm) stage I primary cutaneous malignant melanoma: Long term results of a French multicentric prospective randomized trial on 319 patients
3. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm
4. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial
5. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas
6. Surgical margins and prognostic factors in patients with thick (>4 mm) primary melanoma
7. Surgical management of malignant melanoma
8. Lymph node metastases. Indicators, but not governors of survival
9. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs
10. A prospective randomized study of the efficacy of routine elective lymphadenopathy in management of malignant melanoma; preliminary results
11. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger
12. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm)
13. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: A randomised trial
14. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping
15. A prospective randomized study of regional extremity perfusion in patients with malignant melanoma
16. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: Results of a multicenter randomized phase III trial
17. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: A multi-center trial
18. Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: Credits, debits, and future perspectives
19. The current EORTC Melanoma Cooperative Group adjuvant trial program on malignant melanoma: Prognosis versus efficacy, toxicity and costs
20. Preliminary results of a randomised trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases
21. Interim analysis of a randomized trial of immunotherapy with vaccinia melanoma cell lysates [VMCL] following surgical removal of high risk melanoma
22. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma onoside
23. SWOG-9035: Adjuvant therapy of intermediate-thickness node-negative melanoma with an allogeneic tumor vaccine
24. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine
25. Improved survival in stage III melanoma patients with GM2 antibodies: A randomised trial of adjuvant vaccination with GM 2 ganglioside
26. Significant impact of HLA class I alleles on outcome in T3N0M0 melanoma patients treated with Melacine (MEL): An allogeneic cell lysate vaccine: Prospective analysis of Southwest Oncology Group (SWOG)-9035
27. Melanoma
28. Interferon-alphamediated down-regularion of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule
29. Improved results with the addition of interferon alfa- 2b ro dacarbazine in the treatment of patients with metastatic melagnant melanoma
30. Interferon-alpha 2a does nor improve response or survival when combined with dacarbazide in measatic malignant melanoma: Results of a multi-institutional Australian randomized trial
31. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma
32. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma
33. Phase III trial of dacarbazine versus dacarbazide with interferon alpha2b versus dacarbazide with tamoxifen versus dacarbazide with interferon alpha2b wtih tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative Oncology study
34. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: A Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study
35. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma
36. Interferon alpha-2b adjuvant therapy of highrisk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
37. Randomized trial of interferon alpha- 2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases
38. Randomized surgical adjuvant clinical trial or recombinant interferonalfa-2a in selected patients with malignant melanoma
39. High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190
40. Pooled analysis of four ECOG-Intergroup trials of high-dose interferon alfa-2b (HDI) in 1916 patients with high-risk resected cutaneous melanoma
41. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C 509801
42. Results of adjuvant interferon study in WHO melanoma programme
43. Effect of longterm adkivant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: A randomised trial
44. Adjuvant interferon alpha in high risk melanoma: The Scottish study
45. The European Organization for Research and Treatment of Cancer Melanoma Group trial experience with more than 2000 patients, evaluating adjuvant therapy treatment with low or intermediate doses of interferon alpha-2b
46. Aim high-adjuvant interferon in melanoma (high risk), a United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) randomised study of observation versus adjuvant low dose extended duration interferon alfa-2a in high risk resected malignant melanoma
47. Adjuvant interferon a-2a treatment in resected primary stage II cutaneous melanoma
48. Interferon as an adjuvant treatment for melanoma; registered but not indicated
49. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas
50. Interferon-α as adjuvant therapy for melanoma: A meta-analysis of the randomised trials
51. Role of interferon-alpha in malignant melanoma remains to be determined